Alentis raises €11.1M Series A round
30 April 2019· Allschwil, Switzerland· health, oncology, biotech, b2b, deep_hardware
The funding was used to launch the company and develop its lead humanized monoclonal antibody program targeting liver fibrosis and hepatocellular carcinoma.
Investors
LeadBioMedPartners
Also participating
BpifranceHigh-Tech GründerfondsSchroder AdveqBB Pureos Bioventures
About Alentis
Stage
Series D
Headquarters
Allschwil, Switzerland
Founded
2019
Team Size
51–200
Sectors
healthoncologybiotechb2bdeep_hardware